Oswaldo Cruz Foundation an institution in the service of life

Início do conteúdo


The result of several contracts to technical and scientific cooperation between Fiocruz and the international pharmaceutical industry is to nationalization of the production of strategic inputs for the Brazilian public health, essential dynamic to strengthening of the national pharmaceutical chemistry industry, reducing dependence on foreign and security access of the population to medicines. The estimative is that partnerships provide, by 2017, saving hundreds of millions of dollars to state coffers. In addition to financial return, the public system will incorporate the production technology of inputs, which in the future could be applied in the production of medicines from other therapeutic classes.

These are the major partnerships between Fiocruz and foreign companies in the last five years:

  • Bristol Myers-Squibb Company
  • Chembio Diagnostic Systems Inc
  • Cimab S.A.
  • Eisai Co.
  • Fraunhofer Usa Inc.
  • Genzyme Corporation
  • Glaxosmithkline Biologicals (GSK) S.A.
  • Heber Biotec S.A.
  • Ibio Inc
  • Ukraine Cjsc Indar
  • Lupin Limited
  • Pharnext
  • Sanofi Pasteur S.A.

Back to the topBack